RepliCel Appoints Brooke Hurford as Corporate Secretary and Director, Finance

RepliCel Appoints Brooke Hurford as Corporate Secretary and Director, Finance 
NEWS RELEASE TRANSMITTED BY Marketwired 
FOR: RepliCel Life Sciences Inc. 
TSX VENTURE SYMBOL:  RP
OTCQB SYMBOL:  REPCF 
JULY 16, 2014 
RepliCel Appoints Brooke Hurford as Corporate Secretary and Director, Finance 
VANCOUVER, BRITISH COLUMBIA--(Marketwired - July 16, 2014) - RepliCel Life
Sciences Inc. (the "Company") (TSX VENTURE:RP)(OTCQB:REPCF), today
announced that it has appointed Brooke Hurford, CA as Corporate Secretary and
Director, Finance.  
Ms. Hurford is a Chartered Accountant and holds a degree in Psychology and a
diploma in Accounting from the University of British Columbia. Ms. Hurford has
spent several years in public practice specializing in reviews and audits for
public companies. She recently held a role in the treasury department at the
Bank of Montreal. 
Pursuant to its Stock Option Plan, the Company granted 30,000 options to Ms.
Hurford. The options vest over a one year period and are exercisable at $0.66
per share for five years. 
About RepliCel Life Sciences  
RepliCel is a regenerative medicine company focused on developing autologous
cell therapies that address diseases caused by a deficit of healthy cells
required for normal healing and function such as chronic tendinosis, damaged
skin and pattern baldness. The company's RCT-01 and RCS-01 cell therapies
are designed to treat chronic tendinosis and damaged or aging skin
respectively, using fibroblasts isolated from the sheath of the hair follicle.
Another of the company's pipeline products, RCH-01 for the treatment of
pattern baldness, is manufactured from cells derived from the hair follicle
dermal cup. Shiseido Company, Limited has an exclusive geographic license for
RCH-01 in certain Asian countries including Japan, China and South Korea. All
product candidates are based on RepliCel's innovative technology which
utilizes cells isolated from a patient's own healthy hair follicles to
address specific cellular deficits. For additional information please visit
www.replicel.com.  
On Behalf of the Board   
RepliCel Life Sciences Inc.  
David Hall, President and Chief Executive Officer  
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term
is defined in policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release. 
-30-
FOR FURTHER INFORMATION PLEASE CONTACT: 
CORPORATE CONTACT:
RepliCel Life Sciences
Tammey George, Director of Communications
604-248-8696
tg@replicel.com
or
US INVESTOR RELATIONS:
Westwicke Partners, LLC
Robert H. Uhl, Managing Director
858-356-5932
robert.uhl@westwicke.com
or
CANADIAN INVESTOR RELATIONS:
Christina Cameron
christina@clcameron.com 
INDUSTRY:  Pharmaceuticals and Biotech - Biotech, Pharmaceuticals and Biotech -
Trials 
SUBJECT:  PER 
-0-
-0- Jul/17/2014 01:00 GMT
 
 
Press spacebar to pause and continue. Press esc to stop.